| Title: |
Adjuvant Ovarian Suppression Versus Chemotherapy for Premenopausal, Hormone-responsive Breast Cancer: Quality of Life and Efficacy Tradeoffs. |
| Authors: |
Elena Elkin, Milton Weinstein, Karen Kuntz, Craig Bunnell, Jane Weeks |
| Source: |
Breast Cancer Research & Treatment; Aug2005, Vol. 93 Issue 1, p25-34, 10p |
| Abstract: |
Summary Purpose. Recent clinical trials suggest that adjuvant ovarian suppression may be an equally effective and less toxic alternative to systemic chemotherapy in premenopausal women with hormone-responsive breast cancer. We used a decision-analytic framework to evaluate tradeoffs between efficacy and quality of life in the choice between these treatments. [ABSTRACT FROM AUTHOR] |
|
Copyright of Breast Cancer Research & Treatment is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
